Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — | — | — | — | $0.00 | $0.00 |
| Gross profit | $0.00 | — | — | — | — | — | — | — | — | — |
| Operating income | -$52.7M | -$9.21M | -$6.89M | -$8.56M | $9.87M | -$32.7M | $11.1M | -$8.23M | -$19.5M | -$56.4M |
| Net income | -$43.9M | -$8.84M | -$14.1M | -$8.39M | -$9.85M | -$32.5M | $11.0M | -$7.71M | -$17.6M | -$52.6M |
| EPS (diluted) | -$31.24 | -$6.27 | -$9.04 | -$1.35 | -$0.95 | -$1.58 | — | -$31.04 | -$1.15 | -$1.34 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.9M | -$12.1M | -$5.50M | -$7.56M | -$9.27M | -$10.9M | -$11.4M | -$5.90M | -$14.8M | -$35.8M |
| Capital expenditures | $2.88K | $4.54K | $7.59K | $3.57K | $3.49K | $5.25K | $2.32K | — | — | — |
| Free cash flow | -$15.9M | -$12.1M | -$5.51M | -$7.56M | -$9.28M | -$10.9M | -$11.4M | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10.00M | $1.60M | $12.4M | $4.91M | $6.25M | $5.58M | $2.12M | $9.80M | $94.9M | $97.6M |
| Total assets | $23.3M | $9.89M | $13.3M | $6.37M | $6.87M | $5.99M | $3.40M | $11.7M | $96.7M | $104M |
| Total liabilities | $6.20M | $1.01M | $1.57M | $2.59M | $2.24M | $1.75M | $1.91M | $3.59M | $4.69M | $7.16M |
| Shareholders' equity | $17.1M | $8.88M | $11.8M | $3.77M | $4.63M | $4.24M | $1.49M | $8.10M | $92.0M | $97.1M |
| Retained earnings | -$205M | -$213M | -$228M | -$236M | -$246M | -$278M | -$290M | -$297M | -$315M | -$367M |
| Shares (wtd avg diluted) | 1.41M | 1.41M | 3.79M | 6.74M | 12.6M | 1.26M | 28.6B | 248K | 15.3M | 39.2M |
Every figure is extracted from TENAX THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.